Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patterns, and outcomes in hospitalized patients with an...

Bibliográfalaš dieđut
Váldodahkkit:	Alix Arnaud MS, Samantha Schilsky PhD, MPH, Jackie Lucia BS, Marta Maia MS, Fernando Laredo MS, Ana Paula Marques MD, Hikaru Okada MD, PhD, Andrew W. Roberts PharmD, PhD
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	SAGE Publishing 2024-03-01
Ráidu:	Clinical and Applied Thrombosis/Hemostasis
Liŋkkat:	https://doi.org/10.1177/10760296241241525

Geahča maid

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dahkki: Sriya GUNAWARDENA, MD, et al.
Almmustuhtton: (2023-10-01)

Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
Dahkki: Estcourt, L
Almmustuhtton: (2019)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
Dahkki: Eleni Gavriilaki, et al.
Almmustuhtton: (2023-10-01)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
Dahkki: Antonella Bruzzese, et al.
Almmustuhtton: (2023-07-01)

Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura
Dahkki: Jon Shaffer, et al.
Almmustuhtton: (2022-07-01)

Thrombotic thrombocytopenic purpura with juvenile systemic lupus erythematosus: successful treatment with caplacizumab and rituximab
Dahkki: Tadafumi Yokoyama, et al.
Almmustuhtton: (2024-12-01)

Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
Dahkki: Brandon Tse, et al.
Almmustuhtton: (2023-12-01)

P78 Thrombotic thrombocytopenic purpura (TTP) in an SLE patient successfully treated with plasma exchange, caplacizumab and rituximab
Dahkki: Branimir Anic, et al.
Almmustuhtton: (2024-03-01)

S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY
Dahkki: M. Scully, et al.
Almmustuhtton: (2022-06-01)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
Dahkki: Daan Dierickx, et al.
Almmustuhtton: (2023-08-01)

Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta‐analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura
Dahkki: Niraj Neupane, et al.
Almmustuhtton: (2024-02-01)

Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab
Dahkki: Kim Ditzel, et al.
Almmustuhtton: (2022-04-01)

Homologous In-Radiolabeled Platelet Survival and Sequestration Exploration for Refractory Immunologic Thrombocytopenic purpura in Children: A Strategy to Avoid Unnecessary Splenectomy
Dahkki: Julien Dubois PharmD, et al.
Almmustuhtton: (2024-11-01)

Ingenol mebutate–associated immune thrombocytopenic purpura
Dahkki: Hafsa Zuberi, BS, et al.
Almmustuhtton: (2024-04-01)

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange
Dahkki: Brendy Van Butsel, et al.
Almmustuhtton: (2024-11-01)

Hereditary thrombotic thrombocytopenic purpura
Dahkki: Marie Scully
Almmustuhtton: (2019-10-01)

Inherited thrombotic thrombocytopenic purpura
Dahkki: Miriam Galbusera, et al.
Almmustuhtton: (2009-02-01)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
Dahkki: Javier DE LA Rubia, et al.
Almmustuhtton: (2023-08-01)

Thrombotic thrombocytopenic purpura with terminal pancytopenia.
Dahkki: Ng, S.C., et al.
Almmustuhtton: (1990)

The different faces of thrombotic thrombocytopenic purpura
Dahkki: Paul Knöbl
Almmustuhtton: (2024-11-01)

Campylobacter Jejuni and Thrombotic Thrombocytopenic Purpura
Dahkki: Roman Jaeschke, et al.
Almmustuhtton: (1990-01-01)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
Dahkki: Umer Syed, et al.
Almmustuhtton: (2018-01-01)

Predictors of survival in thrombotic thrombocytopenic purpura
Dahkki: Shruti Chaturvedi, et al.
Almmustuhtton: (2013-05-01)

Tuberculosis presenting as thrombotic thrombocytopenic purpura
Dahkki: Anu Maheshwari, et al.
Almmustuhtton: (2021-01-01)

Diagnostic methods for thrombotic thrombocytopenic purpura
Dahkki: Yesica A. López-Mora, et al.
Almmustuhtton: (2024-01-01)

Diagnostic methods for thrombotic thrombocytopenic purpura
Dahkki: Yesica A. López-Mora, et al.
Almmustuhtton: (2024-01-01)

Acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology in patients with severe disease: completing the landscape of thrombotic thrombocytopenic purpura
Dahkki: Bérangère S. Joly, et al.
Almmustuhtton: (2024-12-01)

Purtscher retinopathy as an initial presentation of thrombotic thrombocytopenic purpura
Dahkki: Tajunisah, I., et al.
Almmustuhtton: (2010)

Clinical case of pregnancy complicated by thrombotic thrombocytopenic purpura
Dahkki: M. V. Semenova, et al.
Almmustuhtton: (2024-06-01)

Subclinical Cardiac Abnormalities in Thrombotic Thrombocytopenic Purpura (TTP) Survivors
Dahkki: Leah Danish, et al.
Almmustuhtton: (2024-01-01)

Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review
Dahkki: Lara Chavaz, et al.
Almmustuhtton: (2024-08-01)

Atypical Thrombotic Thrombocytopenic Purpura Presenting as Stroke
Dahkki: Pradeepthi Badugu, et al.
Almmustuhtton: (2019-01-01)

Thrombotic Thrombocytopenic Purpura Associated with Pneumococcal Sepsis
Dahkki: Jeffrey R Schriber, et al.
Almmustuhtton: (1993-01-01)

Moxifloxacin (Avelox) Induced Thrombotic Thrombocytopenic Purpura
Dahkki: Sikander P. Surana, et al.
Almmustuhtton: (2012-01-01)

Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors
Dahkki: Alexey Youssef, et al.
Almmustuhtton: (2018-01-01)

Acute pancreatitis preceding thrombotic thrombocytopenic Purpura
Dahkki: Julia A M Anderson, et al.
Almmustuhtton: (2007-09-01)

A third form of thrombotic thrombocytopenic purpura?
Dahkki: Bernhard Lammle
Almmustuhtton: (2022-04-01)

More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura”
Dahkki: Flora Peyvandi
Almmustuhtton: (2025-01-01)

Rare Presentation of Refractory Thrombotic Thrombocytopenic Purpura: Jejunal Stricture
Dahkki: Prabath K. Abeysundara, et al.
Almmustuhtton: (2017-10-01)

Approach to Management of Thrombotic Thrombocytopenic Purpura at University of Cincinnati
Dahkki: N. Abdel Karim, et al.
Almmustuhtton: (2013-01-01)